Skip to main content
research report

A Toronto Stock Exchange logo is seen in Toronto in this file photo.© Mark Blinch / Reuters

Globe editors have posted this research report with permission of Thomson Reuters I/B/E/S. This should not be construed as an endorsement of the report's recommendations. For more on The Globe's disclaimers please read here. The following is excerpted from the report:

EARNINGS HIGHLIGHTS

Q1 2017 Y/Y Blended Earnings Growth Estimates:

  • TSX Composite = 29.0 per cent
  • Ex-Energy = 15.9 per cent
  • Valeant Pharmaceuticals International Inc = -33.8 per cent
  • Healthcare Ex- VRX = 13.3 per cent
  • TSX Composite Ex-VRX = 30.2 per cent

Q1 2017 Performance vs. Earnings Expectations:

Eighty-six per cent of the TSX Composite companies have reported Q1 2017 EPS. Of the 203 companies in the index that have reported earnings to date for Q1 2017:

  • 45.9 per cent reported above analyst expectations
  • 41.1 per cent reported below analyst expectations

REVENUE HIGHLIGHTS

Q1 2017 Y/Y Blended Revenue Growth Estimates:

  • TSX Composite = 8.9 per cent
  • Ex-Energy = 3.9 per cent
  • Valeant Pharmaceuticals= -4.1 per cent
  • Healthcare Ex-Valeant Pharmaceuticals = 5.1 per cent
  • TSX Composite Ex-Valeant Pharmaceuticals = 9.1 per cent

Q1 2017 Performance vs. Revenue Expectations:

Of the TSX Composite companies that have reported revenue to date for Q1 2017:

  • 52.2 per cent reported above analyst expectations
  • 47.3 per cent reported below analyst expectations

Click here to see a full copy of the Thomson Reuters I/B/E/S TSX Composite Earnings Scorecard.

Globe app users click here for the full report

Read other research reports here.

Interact with The Globe